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Clinical Case Report
ABSTRACT
Although uncommon in patients under oral therapy, bisphosphonate-related osteonecrosis of the jaw (BRONJ) can be a 
very severe issue. Early intervention with surgical resection should be the preferable method of treating any stage of the 
disease, resulting in better outcomes and decreasing the morbidity of this condition. A 77-year-old female patient attended 
the Special Care Dentistry Centre of the University of São Paulo Faculty of Dentistry (CAPE FOUSP) complaining mainly 
of “an exposed bone that appeared after tooth extraction performed six months earlier”. The patient was diagnosed 
with osteonecrosis associated with bisphosphonate (sodium ibandronate) and surgically treated with removal of bone 
sequestration and antibiotic therapy. The patient was followed up for six years (a total of 6 appointments), presenting 
good general health and no sign of bone exposure. Imaging findings showed no changes related to BRONJ either. 
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INTRODUCTION
Osteoporosis is a bone metabolic disorder (BMD) 
characterized by loss of bone mineral density. Its treatment 
aims to prevent fractures by means of administration of 
medications, such as bisphosphonates (BPs).1
BPs bind to hydroxyapatite crystals, internalizing 
into the bone matrix and can be absorbed by osteoclasts 
during bone resorption (leading to apoptosis), excreted or 
re-captured, and re-incorporated into the skeleton. This 
characteristic results in a lengthy, continuous interference 
with bone turnover and whose bone retention time is 
estimated to be between 1 and 10 years.2 BPs can be classified 
depending on their action pattern, that is, nitrogenated 
or non-nitrogenated, with nitrogen-containing BPs (e.g., 
pamidronate, alendronate, risedronate, ibandronate, and 
zoledronate) being mostly used because they are more 
potent 1. Their absorption depends on the gender, age 
and bone resorption rate of the patient at the time, in 
addition to the administration route, since absorption of 
BPs is less than 1% when orally administered compared 
to the endogenous route, which can reach 50%.2,3
Inhibition of osteoclastic activity, in association with 
anti-anti-angiogenic properties, results consequently 
in decreased bone turnover and hyper-mineralization 
as well as accounts for bone hypo-vascularisation. 
These characteristics added to the inhibition of T cells’ 
function, macrophages and monocytes would lead to 
osteonecrosis of the jaw - one of the most significant 
complications of BPs.2,3
Several risk factors are associated with the 
development of bisphosphonate-related osteonecrosis 
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of the jaw (BRONJ), such as invasive dental procedures 
(e.g., tooth extraction), inflammatory and/or infectious 
conditions, advanced age and dosage and length of 
treatment with BPs. Drug route is also closely related to 
the incidence of BRONJ, which occurs more frequently 
when administered intravenously (1.6 to 14.8%) than 
orally (0.001% to 0.01%).4-7
Although oral route accounts for a few cases of 
BRONJ, they may occur and present significant morbidity 
to the patient,8 leading to pathological fractures of 
the jaw.9 Therefore, it is important to recognize the 
clinical characteristics and the risk factors related to the 
development of BRONJ in these patients.10
CASE REPORT
A 77-year-old female patient attended the 
Special Care Dentistry Centre of the University of São 
Paulo Faculty of Dentistry (CAPE FOUSP) complaining 
mainly of “an exposed bone that appeared after tooth 
extraction performed six months earlier”.
During medical history taking, the patient 
reported no history of chronic use of steroids or 
radiotherapy in the head and neck region. However, 
she reported painful swelling in the mentonian 
region, including abscess and fistula, after 1 year of 
dental treatment. In this clinical context, the dentist 
performed periodontal therapy by scraping all the teeth 
and extracting teeth 33 and 34, including antibiotic 
therapy (cephalexin and amoxicillin with potassium 
clavulanate). However, bone exposure advanced.
The patient was on medications for control of 
type-2 diabetes mellitus (glargine insulin and sitagliptin 
phosphate), cardiopathy, and systemic hypertension 
(salicylic acetyl acid, atenolol, enalapril maleate, and 
hydrochlorothiazide) and dyslipidemia (simvastatin and 
ciprofibrate). She also reported undergoing cardiac 
surgeries (2 mammary and 1 saphenous bypass grafts) 
in 2005 and thyroidectomy in 2011 (using levothyroxine 
sodium). The patient was also taking cholecalciferol and 
tribasic calcium phosphate for control of osteoporosis/
osteopenia for many years as well as sodium ibandronate 
for two years. Pantoprazole was also used.
Clinical examination showed the exposure of 
bone and alveolar ridge in the region of teeth #33 and 
#34 (Figure 1A). Panoramic radiograph demonstrated 
Figure 1. A – Exposure of bone and alveolar ridge in the region of teeth #33 and #34 an intraoral aspect; B – Area 
of bone sequestration spreads across the body of the mandible (symphysis region) to the region of pre-molars; 
C – Cone-beam computed tomography; D –Histological exam – H&E stained section showing completely necrotic 
bone trabeculae
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evidence of radiopaque image suggestive of bone 
necrosis involving the region of lower incisors. 
An extensive area of bone sequestration spread 
across the body of the mandible (symphysis region) 
to the region of pre-molars (Figure 1B). Cone-beam 
computed tomography showed a radiolucent, well-
defined injury, covering the area of teeth #35 to 
#43, with impairment of buccal and lingual cortical 
bones, but with mandibular basal lamina preserved 
(Figure 1C).
After the incisional biopsy, histological sections 
stained with hematoxylin/eosin revealed a fragment 
of lamellar bone tissue with uniform distribution of 
lacunae and empty feeding canals, including colonies 
of bacteria closely related to it (Figure 1D).
The patient was diagnosed with osteonecrosis 
associated with the use of bisphosphonate (sodium 
ibandronate). She was surgically treated with removal of 
bone sequestration and teeth (Figures 2A, 2B, and 2C), 
including antibiotic therapy.
After the surgery, the patient presented proper 
healing and no sign of new bone exposure and/or 
surgical wound dehiscence (Figure 2D).
The patient was followed up for six years (a total of 6 
appointments), presenting good general health, no sign 
of bone exposure, and did not have paresthesia. Imaging 
findings showed no changes related to BRONJ either.
DISCUSSION
Oral BPs have been usually used for the treatment 
of osteoporosis. Despite the low incidence of BRONJ 
in these patients,7 some cases have already been 
reported8,9,11,12 and presented high morbidity, leading 
to pathological fractures.12
The patient, who develops osteoporosis, belongs, 
almost always to the age group with other systemic 
chronic diseases, which are also additional risk factors 
for BRONJ. Diseases like diabetes, hypertension, 
dyslipidemia, and rheumatoid arthritis can affect micro-
Figure 2. A – Necrotic area involving bone and teeth; B – Surgical treatment with removal of bone sequestration; 
C – After the removal of bone sequestration and teeth; D – Surgical follow up (7 days). No sign of new bone 
exposure and/or surgical wound dehiscence.
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vascularization, and as such they are risk factors for 
the development of BRONJ.13,14
In general, the most used drugs in the treatment 
of osteoporosis are alendronate, risedronate, and 
ibandronate. These medications can be ordered 
according to their potency ( i .e. r isedronate > 
ibandronate > alendronate) and bone-binding affinity 
(i.e. alendronate > ibandronate > risedronate).3
In the present case, we have identified several risk 
factors for the development of BRONJ, namely: age, 
comorbidities potentially affecting vascularization, 
and the use of ibandronate. Although the literature 
suggests that the risk of BRONJ development in patients 
on oral BPs might be associated with longer use of 
them (i.e., > 3 years), this observation is particularly 
related to the use of alendronate.15-17 Ibandronate is 
the least reported drug in epidemiological surveys, but 
case reports are pointing to the development of BRONJ 
after 2 years of continuous use of the drug.8,9,11,12
Another important issue is the choice of treatment 
of BRONJ, which had been extremely conservative, 
based on antibiotics and letting invasive measures 
for extensive lesions.14 The literature has recently 
shown that the disease can progress if not treated 
or conservatively controlled. Early intervention with 
surgical resection should be the preferred method of 
treating any disease stage, resulting in better outcomes 
and decreasing its morbidity.18 This information 
has encouraged us to carry out direct, conclusive 
treatment, and therefore we opted for a surgical 
approach regarding the affected bone. Although the 
treatment has been effective, the delay in performing 
it led to a substantial loss of hard tissue, which did not 
allow us to achieve the patient’s oral rehabilitation.
Prior to the surgical procedure, the patient’s 
doctor discontinued the use of ibandronate. This is 
still a point of discussion. The American Association of 
Oral and Maxillofacial Surgeons, in its position paper, 
recommends (on the empirical basis) the discontinuation 
of oral BPs three months before and three months after 
the surgery. However, multicentric prospective studies 
showed that such recommendation has no benefit 
regarding the prevention of BRONJ, regardless of the 
administration route (i.e., oral or intravenous).6,19
In addition, a BP drug holiday can increase the risk of 
osteoporotic femur fracture.20 The significant mortality 
rate in patients after osteoporotic fractures21 and the 
low incidence7 and high likelihood of complete BRONJ 
healing18 lead us to recommend that BPs should not 
be discontinued in osteoporotic patients.
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